General information/press room, American Thyroid Association (2025) Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: A systematic literature review, International Journal of Molecular Sciences (2024) Diabetes mellitus and thyroid cancers: risky correlation, underlying mechanisms and clinical prevention, Diabetes, Metabolic Syndrome, and Obesity (2024) Hyperthyroidism, Cleveland Clinic (2024) Hyperthyroidism, MedLinePlus (2024) Hypothyroidism, Cleveland Clinic (2024) Implications of GLP-1 receptor agonist on thyroid function: A literature review of its effects on thyroid volume, risk of cancer, functionality and TSH levels, Biomolecules (2024) Safety of semaglutide, Frontiers in Endocrinology (2021) Semaglutide injection, MedLinePlus (2025) Semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth, The Journal of Clinical Endocrinology and Metabolism (2025) Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report, Journal of the American Pharmacists Association (2024) Use of GLP-1 receptor agonists and occurrence of thyroid disorders: A meta-analysis of randomized controlled trials, Frontiers in Endocrinology (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
This makes it suitable for extended peptide cycles or anti-aging protocols without risking endocrine shutdown
The beneficial effect of GLP-1RAs on the state of the neurovascular unit has been shown, which can significantly contribute to the neuroprotective effects of these drugs in NDD [48]
This ensures the substance is actually Retatrutide and not a cheaper alternative like Semaglutide
If you are also taking an SGLT2 inhibitor (such as dapagliflozin, empagliflozin, or canagliflozin), be aware that these medications are known to increase the risk of genital yeast infections
Jones et al ., 2018), and the use of the cleavable BG-Lumi4-Tb to monitor GLP-1R recycling in combination with a fluorescent antagonist ligand was recently described by our group (Pickford et al ., 2020)
